Skip to content

Clinical observation and mechanism study of Yiqi Tongyang prescription in the treatment of chronic immune thrombocytopenia

Clinical observation and mechanism study of Yiqi Tongyang prescription in the treatment of chronic immune thrombocytopenia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043514
Enrollment
Unknown
Registered
2021-02-21
Start date
2021-02-10
Completion date
Unknown
Last updated
2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune thrombocytopenia

Interventions

Sponsors

Xiyuan Hospital, Chinese Academy of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The patients with definite diagnosis of ITP, whose course of disease is more than 12 months, aged 18-75 years, 80 x 10^9 /L > PLT >10 x 10 ^ 9 / L or bleeding symptoms; 2. Patients with purpura of spleen and kidney yang deficiency syndrome of TCM; 3. Patients with informed consent, voluntary participation and regular medication. 4. Healthy people with informed consent, voluntary participation and age of 18-60.

Exclusion criteria

Exclusion criteria: 1. Patients who received high-dose glucocorticoid pulse therapy within 3 months before treatment. 2. The subjects who received other treatments except hormone within 30 days before treatment, or participated in other clinical studies, which may have an impact on the observation indexes of curative effect. 3. Patients with severe immune deficiency or severe gastrointestinal and / or visceral bleeding. 4. Patients with severe heart, liver and kidney dysfunction: serum creatinine is higher than the upper limit of normal value; Alanine aminotransferase, aspartate aminotransferase and bilirubin were 2 times higher than normal; NYHA grade >= grade II; Or mental illness patients. 5. Pregnant, lactating women or subjects with allergic constitution.

Design outcomes

Primary

MeasureTime frame
Platelet count;Immune related cytokines;T/B lymphocyte subsets;

Countries

China

Contacts

Public ContactXu Yonggang

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine

xyg312@163.com+86 13910608561

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026